2. Search Result
Search Result
Results for "

NMT

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

1

Natural
Products

1

Antibodies

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153021
    NMT-IN-1

    		Parasite Infection
    NMT-IN-1 (compound 9) is a potent N-Myristoyltransferase (NMT) Inhibitor with IC50 values of 31 and 66 μM for TbNMT and hNMT, respectively. NMT-IN-1 can be used in research of african trypanosomiasis .
    NMT-IN-1
  • HY-103056
    DDD85646

    IMP-366

    		 DNA/RNA Synthesis Parasite Infection
    DDD85646 (IMP-366) is an orally active of trypanosoma brucei N-myristoyltransferase (TbNMT IC50=2 nM; hNMT IC50=4 nM). The enzyme N-myristoyltransferase (NMT) is a potential agent target for human African trypanosomiasis .
    DDD85646
  • HY-126833A
    Myristoyl coenzyme A lithium
    1 Publications Verification

    		 Endogenous Metabolite Infection Cancer
    Myristoyl coenzyme A lithium is lithium-labeled myristoylated coenzyme A (CoA). Myristoylation is an essential process in viruses and is generally controlled by N-myristoyltransferase (NMT). And NMT is more active in colon epithelial tumors than in normal cells. Reduced Ccoenzyme A (CoA) is known to be a key regulator of NMT activity, whereas oxidized CoA does not allow NMT to promote myristoylation. Myristoyl coenzyme A blocks the demyristoylation process and has potential anticancer and antiviral mechanisms.
    Myristoyl coenzyme A lithium
  • HY-147308
    PCLX-001
    2 Publications Verification

    		 N-myristoyltransferase Cancer
    PCLX-001 is an orally acitve, small-molecule, dual N-myristoyltransferase (NMT) inhibitor, with IC50s of 5 nM (NMT1) and 8 nM (NMT2), respectively. PCLX-001 can induce cell apoptosis, has anti-cancer activity, inhibits early B cell receptor (BCR) signaling, and can be used to study malignant lymphoma .
    PCLX-001
  • HY-158364
    NMT-IN-3

    		Parasite Infection
    NMT-IN-3 is an inhibitor of N-myristoyltransferase (NMT). The IC50 of NMT-IN-3 for Plasmodium vivax NMT is 38 mM .
    NMT-IN-3
  • HY-RS09389
    NMT1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    NMT1 Human Pre-designed siRNA Set A contains three designed siRNAs for NMT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NMT1 Human Pre-designed siRNA Set A
    NMT1 Human Pre-designed siRNA Set A
  • HY-RS09390
    NMT2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    NMT2 Human Pre-designed siRNA Set A contains three designed siRNAs for NMT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NMT2 Human Pre-designed siRNA Set A
    NMT2 Human Pre-designed siRNA Set A
  • HY-122134
    SC-58272

    		Fungal Infection
    SC-58272 is a potent and selective dipeptide N-myristoyltransferase (Nmt) inhibitor with an IC50 of 56 nM for C. albicans (strain B311) Nmt. SC-58272 shows 250-fold selective for the fungal enzyme compared to human enzyme .
    SC-58272
  • HY-126833
    Myristoyl coenzyme A

    		Endogenous Metabolite Infection Cancer
    Myristoyl coenzyme A is a myristoylated coenzyme A (CoA). Myristoylation is an essential process in viruses and is generally controlled by N-myristoyltransferase (NMT). And NMT is more active in colon epithelial tumors than in normal cells. Reduced Ccoenzyme A (CoA) is known to be a key regulator of NMT activity, whereas oxidized CoA does not allow NMT to promote myristoylation. Myristoyl coenzyme A blocks the demyristoylation process and has potential anticancer and antiviral mechanisms.
    Myristoyl coenzyme A
  • HY-132211
    3-Thiatetradecanoic acid

    		PPAR Others
    3-Thiatetradecanoic acid is a substrate of N-myristoyltransferase (NMT), which is involved in the metabolism of thiofatty acids .
    3-Thiatetradecanoic acid
  • HY-112258
    IMP-1088
    4 Publications Verification

    		 DNA/RNA Synthesis Infection
    IMP-1088 is a potent human N-myristoyltransferases NMT1 and NMT2 dual inhibitor with IC50s of <1 nM for HsNMT1 and HsNMT2. IMP-1088 has a Kd of <210 pM for HsNMT1. IMP-1088 efficiently blocks rhinovirus replication by blocking rhinovirus virus-encoded protein (VP0) N-myristoylation. IMP-1088 protects host cells from the cytotoxic effects of viral infection .
    IMP-1088
  • HY-136625
    LY134046

    		Others Neurological Disease
    LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT). Its cardiovascular activity was studied in anesthetized spontaneously hypertensive rats (SHR). Acute intraperitoneal injection of 10 and 20 mg/kg of LY134046 caused minimal cardiovascular changes, while 40 mg/kg resulted in a sustained decrease in mean arterial blood pressure and heart rate. This hypotension and bradycardia occurred rapidly and occurred when brain NMT activity was significantly inhibited. However, norepinephrine concentrations in rat brains were not significantly reduced at the time when LY134046-induced blood pressure and heart rate effects were maximal. The acute cardiovascular activity of LY134046 was not significantly affected by pretreatment of SHR with phentolamine, propranolol, or atropine, and LY134046 reduced heart rate in suspended SHR. In addition, acute or chronic administration of LY134046 did not antagonize the vasoconstrictor responses induced by sympathetic nerve stimulation or exogenous norepinephrine. These observations suggest that LY134046 does not interact with adrenergic or cholinergic receptors and that its hypotensive and bradycardic effects do not require neurogenic tension. Chronic intraperitoneal administration of LY134046 (40 mg/kg/day) resulted in a sustained and significant inhibition of hypothalamic and brainstem NMT activity, leading to central norepinephrine depletion. During chronic treatment, norepinephrine and dopamine concentrations increased in the brainstem and hypothalamus of SHR. Despite chronic inhibition of central NMT and norepinephrine depletion, cardiovascular parameters in SHR treated groups were not significantly different from those in saline-injected controls. Chronic treatment with LY134046 did not result in tolerance to its central biochemical effects or acute cardiovascular activity. The present study does not support the idea that norepinephrine-producing neurons are involved in the central regulation of cardiovascular function, because the hypotension and bradycardia induced by acute administration of LY134046 occurred before a significant decrease in hypothalamic norepinephrine concentrations, whereas chronic inhibition of central NMT and depletion of norepinephrine resulted in minimal changes in baseline cardiovascular parameters.
    LY134046
  • HY-164285
    MYX1715

    		ADC Cytotoxin N-myristoyltransferase Cancer
    MYX1715 is an inhibitor of N-Myristoyltransferase (NMT) with a KD value of 0.09 nM. MYX1715 inhibits the proliferation of LU0884 and LU2511 with IC50 values of 44 nM and 9 nM. MYX1715 exhibits antitumor efficacy against neuroblastoma and gastric cancer in mouse models. MYX1715 can be used as ADC toxin .
    MYX1715

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: